
Coromandel (COROMANDEL) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
70.4B
Gross Profit
18.0B
25.61%
Operating Income
6.6B
9.39%
Net Income
5.0B
7.12%
EPS (Diluted)
₹17.12
Balance Sheet Metrics
Total Assets
189.3B
Total Liabilities
77.0B
Shareholders Equity
112.2B
Debt to Equity
0.69
Cash Flow Metrics
Revenue & Profitability Trend
Coromandel Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 159.4B | 138.6B | 151.3B | 123.2B | 108.3B |
Cost of Goods Sold | 179.9B | 166.3B | 236.7B | 143.6B | 98.0B |
Gross Profit | -20.5B | -27.7B | -85.4B | -20.5B | 10.3B |
Gross Margin % | -12.9% | -20.0% | -56.5% | -16.6% | 9.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 13.9B | 12.0B | 11.8B | 10.7B | 9.2B |
Other Operating Expenses | 11.8B | 10.3B | 10.1B | 8.2B | 8.4B |
Total Operating Expenses | 25.7B | 22.4B | 21.9B | 18.9B | 17.6B |
Operating Income | 24.3B | 22.4B | 29.1B | 20.8B | 18.9B |
Operating Margin % | 15.2% | 16.2% | 19.2% | 16.9% | 17.5% |
Non-Operating Items | |||||
Interest Income | 2.4B | 1.9B | 1.6B | 1.0B | 416.4M |
Interest Expense | 2.5B | 1.8B | 1.8B | 678.5M | 983.5M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 27.3B | 21.9B | 27.0B | 20.5B | 17.9B |
Income Tax | 6.7B | 5.5B | 6.9B | 5.2B | 4.6B |
Effective Tax Rate % | 24.7% | 25.0% | 25.5% | 25.4% | 25.6% |
Net Income | 20.5B | 16.4B | 20.1B | 15.3B | 13.3B |
Net Margin % | 12.9% | 11.8% | 13.3% | 12.4% | 12.3% |
Key Metrics | |||||
EBITDA | 28.1B | 25.9B | 30.5B | 22.9B | 20.6B |
EPS (Basic) | ₹70.23 | ₹55.81 | ₹68.51 | ₹52.09 | ₹45.34 |
EPS (Diluted) | ₹70.12 | ₹55.75 | ₹68.38 | ₹51.98 | ₹45.22 |
Basic Shares Outstanding | 294539422 | 294289087 | 293814998 | 293433933 | 293165645 |
Diluted Shares Outstanding | 294539422 | 294289087 | 293814998 | 293433933 | 293165645 |
Income Statement Trend
Coromandel Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.5B | 11.2B | 13.9B | 7.1B | 6.9B |
Short-term Investments | 41.4B | 24.4B | 334.9M | 10.2B | 665.7M |
Accounts Receivable | 12.3B | 13.9B | 5.9B | 2.6B | 5.0B |
Inventory | 47.7B | 46.1B | 44.2B | 36.6B | 26.0B |
Other Current Assets | 6.9B | 11.0B | 6.9B | 5.0B | 2.4B |
Total Current Assets | 132.3B | 121.2B | 102.4B | 83.4B | 65.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.7B | 8.7M | 8.7M | 8.7M | 5.7M |
Goodwill | 6.4B | 6.4B | 327.2M | 294.0M | 233.8M |
Intangible Assets | 728.7M | 681.3M | 320.8M | 287.6M | 227.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 136.5M | 42.5M | 41.0M | 44.8M | 14.9M |
Total Non-Current Assets | 57.0B | 37.3B | 39.9B | 29.4B | 23.7B |
Total Assets | 189.3B | 158.5B | 142.3B | 112.8B | 89.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 60.3B | 53.6B | 53.1B | 39.1B | 29.2B |
Short-term Debt | 1.8B | 818.6M | 295.0M | 240.7M | 230.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.5B | 1.3B | 1.5B | 1.9B | 727.3M |
Total Current Liabilities | 69.9B | 58.6B | 58.6B | 44.7B | 33.0B |
Non-Current Liabilities | |||||
Long-term Debt | 6.0B | 4.1B | 3.6B | 3.7B | 3.6B |
Deferred Tax Liabilities | 836.6M | 827.3M | 590.9M | 659.7M | 575.6M |
Other Non-Current Liabilities | 63.3M | 69.6M | 76.9M | 77.9M | 81.0M |
Total Non-Current Liabilities | 7.1B | 5.4B | 4.7B | 4.6B | 4.4B |
Total Liabilities | 77.0B | 64.0B | 63.3B | 49.3B | 37.4B |
Equity | |||||
Common Stock | 294.6M | 294.4M | 294.0M | 293.5M | 293.4M |
Retained Earnings | 84.4B | 68.0B | 52.8B | 36.2B | 24.4B |
Treasury Stock | 366.6M | 249.4M | 0 | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 112.2B | 94.5B | 79.1B | 63.6B | 51.5B |
Key Metrics | |||||
Total Debt | 7.8B | 4.9B | 3.9B | 3.9B | 3.8B |
Working Capital | 62.4B | 62.6B | 43.9B | 38.7B | 32.2B |
Balance Sheet Composition
Coromandel Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 27.3B | 21.9B | 27.0B | 20.5B | 17.9B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 106.1M | 63.0M | 77.1M | 28.1M | 39.9M |
Working Capital Changes | -2.8B | -4.0B | -30.7B | -6.4B | 29.8B |
Operating Cash Flow | 21.4B | 17.6B | -3.3B | 13.8B | 48.4B |
Investing Activities | |||||
Capital Expenditures | -4.3B | -5.2B | -5.7B | -2.8B | -1.9B |
Acquisitions | -178.4M | -2.2B | -1.6B | 0 | -120.0M |
Investment Purchases | -45.6B | -68.6B | -3.1B | 0 | 0 |
Investment Sales | 29.1B | 61.9B | 12.8B | 0 | 4.0M |
Investing Cash Flow | -21.0B | -14.8B | 12.8B | -13.0B | -2.0B |
Financing Activities | |||||
Share Repurchases | -154.8M | -249.4M | 0 | - | - |
Dividends Paid | -3.5B | -1.9B | -3.5B | -3.5B | -5.3B |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | -16.2B |
Financing Cash Flow | -4.0B | -1.5B | -3.3B | -3.5B | -37.6B |
Free Cash Flow | 16.1B | 9.0B | -142.7M | 18.0B | 39.6B |
Net Change in Cash | -3.7B | 1.3B | 6.2B | -2.7B | 8.7B |
Cash Flow Trend
Coromandel Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
31.54
Forward P/E
42.74
Price to Book
6.42
Price to Sales
2.70
PEG Ratio
42.74
Profitability Ratios
Profit Margin
8.56%
Operating Margin
9.39%
Return on Equity
18.41%
Return on Assets
10.92%
Financial Health
Current Ratio
1.89
Debt to Equity
6.95
Beta
0.27
Per Share Data
EPS (TTM)
₹76.72
Book Value per Share
₹376.70
Revenue per Share
₹896.98
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
coromandel | 712.9B | 31.54 | 6.42 | 18.41% | 8.56% | 6.95 |
UPL | 622.8B | 3.00 | 1.63 | 2.01% | 0.09% | 105.06 |
PI Industries | 594.5B | 35.84 | 5.85 | 17.58% | 20.81% | 1.81 |
UPL | 565.8B | 50.76 | 1.99 | 2.01% | 2.55% | 66.35 |
Sumitomo Chemical | 288.1B | 51.80 | 9.93 | 17.40% | 16.55% | 1.79 |
Bayer CropScience | 247.6B | 41.72 | 8.69 | 19.93% | 10.29% | 3.69 |
Financial data is updated regularly. All figures are in the company's reporting currency.